for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neovasc Inc

NVCN.TO

Latest Trade

1.84CAD

Change

-0.04(-2.13%)

Volume

209,306

Today's Range

1.77

 - 

1.96

52 Week Range

0.89

 - 

5.30

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.88
Open
1.91
Volume
209,306
3M AVG Volume
3.99
Today's High
1.96
Today's Low
1.77
52 Week High
5.30
52 Week Low
0.89
Shares Out (MIL)
28.88
Market Cap (MIL)
54.29
Forward P/E
-0.63
Dividend (Yield %)
--

Latest Developments

More

Neovasc Responds To FDA Not-Approvable Letter Regarding Neovasc Reducer™

Neovasc Inc Files For Mixed Shelf Of Up To $125 Mln – SEC Filing

Neovasc Announces Third Quarter Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neovasc Inc

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Industry

Medical Equipment & Supplies

Contact Info

Richmond, 5138-13562 Maycrest Way

RICHMOND, BC

V6V 2J7

Canada

+1.604.2704344

https://www.neovasc.com/

Executive Leadership

Steven D. Rubin

Independent Chairman of the Board

Fred Colen

President, Chief Executive Officer

Christopher Clark

Chief Financial Officer, Corporate Secretary

Bill Little

Chief Operating Officer

Vicki Lee Bebeau

Vice President - Clinical and Regulatory Affairs

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-280.000

2018

-56.500

2019

-5.550

2020(E)

-2.360
Price To Earnings (TTM)
--
Price To Sales (TTM)
21.45
Price To Book (MRQ)
51.76
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1,556.97
LT Debt To Equity (MRQ)
1,378.93
Return on Investment (TTM)
-618.15
Return on Equity (TTM)
-216.01

Latest News

Latest News

BRIEF-Neovasc Announces Circulatory System Devices Panel Meeting Date For Neovasc Reducer™ Device

* NEOVASC ANNOUNCES CIRCULATORY SYSTEM DEVICES PANEL MEETING DATE FOR NEOVASC REDUCER™ DEVICE

BRIEF-Neovasc Announces Positive Interim Results From Reducer-I Study

* NEOVASC ANNOUNCES POSITIVE INTERIM RESULTS FROM REDUCER-I STUDY

BRIEF-Neovasc Regains Compliance With Nasdaq Minimum Market Value Rule

* NEOVASC REGAINS COMPLIANCE WITH NASDAQ MINIMUM MARKET VALUE RULE Source text for Eikon: Further company coverage:

BRIEF-Neovasc Announces Closing Of $11.5 Mln Registered Direct Offering Priced At-The-Market

* NEOVASC ANNOUNCES CLOSING OF $11.5 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET Source text for Eikon: Further company coverage:

BRIEF-Neovasc Announces $11.5 Million Registered Direct Offering Priced At-The-Market

* NEOVASC ANNOUNCES $11.5 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Neovasc Has Filed For CE Mark For Tiara TA Transapical Mitral Valve Replacement System

* NEOVASC HAS FILED FOR CE MARK FOR TIARA TA TRANSAPICAL MITRAL VALVE REPLACEMENT SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Neovasc Says Revamped Capital Structure Will Substantially Improve Ability To Raise Additional Equity Capital

* NEOVASC INC - BELIEVES REVAMPED CAPITAL STRUCTURE WILL SUBSTANTIALLY IMPROVE ABILITY TO RAISE ADDITIONAL EQUITY CAPITAL Source text for Eikon: Further company coverage:

BRIEF-Neovasc Announces Receipt Of Nasdaq Extension To Satisfy Market Cap Rule

* NEOVASC ANNOUNCES RECEIPT OF NASDAQ EXTENSION TO SATISFY MARKET CAP RULE Source text for Eikon: Further company coverage:

BRIEF-Neovasc Says Qtrly Loss Per Share $1.45

* NEOVASC ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Neovasc Had $14.1M Cash On Hand Following Early Jan Capital Raise

* NEOVASC INC - HAD $14.1M CASH ON HAND FOLLOWING EARLY JAN CAPITAL RAISE, & CURRENT CASH IS EXPECTED TO LAST UNTIL AUGUST OF THIS YEAR

BRIEF-Neovasc - Achieved Design Freeze For Fully Retrievable Transfemoral Trans-Septal Tiara System

* NEOVASC - ACHIEVED DESIGN FREEZE FOR FULLY RETRIEVABLE TRANSFEMORAL TRANS-SEPTAL TIARA SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Neovasc's Management And Board Of Directors Urge Shareholders To Vote In Favor Of The Proposed Reverse Stock Split

* NEOVASC'S MANAGEMENT AND BOARD OF DIRECTORS URGE SHAREHOLDERS TO VOTE IN FAVOR OF THE PROPOSED REVERSE STOCK SPLIT AT THE UPCOMING ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

BRIEF-Neovasc Qtrly Operating Losses $6.5 Million

* NEOVASC INC - QTRLY OPERATING LOSSES & COMPREHENSIVE LOSSES WERE $6.5 MILLION & $55.5 MILLION, RESPECTIVELY, OR $0.38 BASIC AND DILUTED LOSS PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Neovasc Regains Compliance With NASDAQ Minimum Market Value Rule

* NEOVASC REGAINS COMPLIANCE WITH NASDAQ MINIMUM MARKET VALUE RULE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up